Treatment of Newly Diagnosed Central Malignant Germ Cell Tumor People With Teniposide Injection Combined With Cisplatin.

Recruiting Phase 2 Interventional Study
GCT Germ Cell Tumor Central Malignant Germ Cell Tumor
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
5 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
40 (estimated)
Sponsor
Chengcheng Guo · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This trial is a prospective single arm intervention study, conducting clinical research on marketed drugs. Adverse drug reactions are controllable and the risk is low, with an estimated total of 40 cases. The main objective is to evaluate the safety and efficacy of teniposide combined with cisplatin in the treatment of newly diagnosed central malignant germ cell tumors, and to conduct drug monitor…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Must have at least one measurable lesion defined by RANO criteria * The initial diagnosis has been confirmed as central malignant germ cell tumor * Expected survival period ≥ 6 months * Absolute neutrophil ≥1.0×10\^9/L; Platelet ≥100.0×10\^9/L * Aspertate aminotransferase and …
Contacts

chengcheng Guo, Doctor of Medicine

020-87343890

guochch@sysucc.org.cn

CONTACT